Bridging the Gap: New Collaborations to Drive Antimicrobial Innovation
This virtual event launched the AMR Action Fund, a partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The fund will invest approximately $1 billion to ensure a robust and diverse pipeline of new medicines to treat drug-resistant infections.
Visit www.AMRActionFund.com to learn more.
Speakers (in order of appearance):
- David Ricks, Chairman and CEO, Eli Lilly and Company
- Michelle McMurry-Heath, President and CEO, BIO
- Brandon Noble, former NFL player
- Stephen J. Ubl, President and CEO, PhRMA
- Ken Frazier, Chairman and CEO, Merck
- Albert Bourla, Chairman and CEO, Pfizer
- Priscilla VanderVeer, Vice President, PhRMA
- ADM Brett P. Giroir, MD, Assistant Secretary for Health
- Senator Bob Casey (D-PA)
- Senator Bill Cassidy, MD (R-LA)
- Scott Gottlieb, resident fellow, American Enterprise Institute – moderator
- Helen Boucher, MD, board member and treasurer, Infectious Disease Society of America
- Kathy Talkington, director, Health Programs, The Pew Charitable Trusts
- Kevin Outterson, executive director and principal investigator, CARB-X
- Ramani Varanasi, founder/president/CEO, X-Biotix
- Michael Boyle, MD, president and CEO, Cystic Fibrosis Foundation
Bridging the Gap: New Collaborations to Drive Antimicrobial Innovation Event Video
A virtual event hosted by PhRMA, IFPMA and BIO announced the launch of the AMR Action Fund, a partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The fund will invest approximately $1 billion to ensure a robust and diverse pipeline of new medicines to treat drug-resistant infections.
Watch the video of the event here.